Skip to main content
    I

    Iovance Biotherapeutics Inc (IOVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.55
    -0.21 (-2.71%)

    Market Cap: $3.59B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Iovance Biotherapeutics Inc (IOVA) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Iovance Biotherapeutics (IOVA) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Iovance Biotherapeutics reported EPS of -$0.05, above the -$0.09 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    30%(12/40)
    Avg Surprise
    -1.83%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.08
    Range-$0.12 - -$0.04
    12 analysts
    Revenue Consensus
    $131.23M
    Range$122.29M - $141.61M
    11 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.04
    Range-$0.08 - -$0.02
    7 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.09+55.1%
    60d ago-$0.09+55.1%
    30d ago-$0.08+49.8%
    7d ago-$0.08+45.9%
    Current-$0.04
    Revenue Consensus
    $133.90M
    Range$124.93M - $145.21M
    6 analysts

    Next Report

    IOVA has an expected report date of Feb 22, 2027.

    IOVA Earnings Call

    The latest IOVA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, IOVA beat 12, missed 22 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $121.47M, up 80.1% from $67.45M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.05-$0.09-$0.10 - -$0.07+44.44%BeatN/A84 up, 0 downNov 5, 2026$121.47M
    Jun 30, 2026-$0.11-$0.17N/A+35.29%BeatN/A7N/AAug 6, 2026$99.31M
    Mar 31, 2026-$0.19-$0.15-$0.22 - -$0.08-23.78%MissN/A80 up, 2 downMay 7, 2026$71.43M
    Dec 31, 2025-$0.18-$0.18-$0.21 - -$0.140.00%In lineN/A80 up, 1 downFeb 24, 2026$86.77M
    Sep 30, 2025-$0.25-$0.26-$0.30 - -$0.22+3.85%BeatN/A95 up, 2 downNov 6, 2025$67.45M
    Jun 30, 2025-$0.33-$0.29-$0.34 - -$0.22-13.79%MissN/A90 up, 8 downAug 7, 2025$59.95M
    Mar 31, 2025-$0.36-$0.24-$0.26 - -$0.18-50.00%MissN/A101 up, 1 downMay 8, 2025$49.32M
    Dec 31, 2024-$0.26-$0.27-$0.36 - -$0.23+2.84%BeatN/A102 up, 4 downFeb 27, 2025$73.69M
    Sep 30, 2024-$0.28-$0.30-$0.35 - -$0.25+6.67%BeatN/A130 up, 0 downNov 7, 2024$58.55M
    Jun 30, 2024-$0.34-$0.35-$0.44 - -$0.29+2.86%BeatN/A121 up, 2 downAug 8, 2024$31.11M
    Mar 31, 2024-$0.42-$0.42-$0.50 - -$0.320.00%In lineN/A120 up, 0 downMay 9, 2024$715000
    Dec 31, 2023-$0.45-$0.43-$0.48 - -$0.34-4.65%MissN/A133 up, 2 downFeb 28, 2024$482000
    Sep 30, 2023-$0.46-$0.46-$0.52 - -$0.410.00%In lineN/A130 up, 0 downNov 7, 2023$469000
    Jun 30, 2023-$0.47-$0.79-$1.72 - -$0.41+40.51%BeatN/A130 up, 0 downAug 8, 2023$238000
    Mar 31, 2023-$0.50-$0.73-$1.52 - -$0.49+31.51%BeatN/A140 up, 0 downMay 9, 2023N/A
    Dec 31, 2022-$0.64-$0.64-$0.70 - -$0.530.00%In lineN/A141 up, 0 downFeb 28, 2023N/A
    Sep 30, 2022-$0.63-$0.64-$0.70 - -$0.56+1.56%BeatN/A140 up, 0 downNov 3, 2022N/A
    Jun 30, 2022-$0.63-$0.61-$0.70 - -$0.53-3.28%MissN/A141 up, 0 downAug 4, 2022N/A
    Mar 31, 2022-$0.58-$0.63-$0.73 - -$0.57+7.94%BeatN/A140 up, 0 downMay 5, 2022N/A
    Dec 31, 2021-$0.63-$0.56-$0.58 - -$0.53-12.50%MissN/A14N/AFeb 24, 2022N/A
    Sep 30, 2021-$0.55-$0.53-$0.58 - -$0.48-3.77%MissN/A144 up, 0 downNov 4, 2021N/A
    Jun 30, 2021-$0.53-$0.51-$0.57 - -$0.46-3.92%MissN/A14N/AAug 5, 2021N/A
    Mar 31, 2021-$0.51-$0.49-$0.60 - -$0.44-4.08%MissN/A14N/AMay 6, 2021N/A
    Dec 31, 2020-$0.47-$0.44-$0.50 - -$0.38-6.82%MissN/A12N/AFeb 25, 2021N/A
    Sep 30, 2020-$0.40-$0.46-$0.54 - -$0.39+13.04%BeatN/A12N/ANov 5, 2020N/A
    Jun 30, 2020-$0.47-$0.52-$0.56 - -$0.47+9.62%BeatN/A12N/AAug 6, 2020N/A
    Mar 31, 2020-$0.55-$0.51-$0.65 - -$0.42-7.84%MissN/A12N/AMay 5, 2020N/A
    Dec 31, 2019-$0.50-$0.42-$0.45 - -$0.40-19.05%MissN/A10N/AFeb 25, 2020N/A
    Sep 30, 2019-$0.40-$0.39-$0.43 - -$0.37-2.56%MissN/A9N/ANov 4, 2019N/A
    Jun 30, 2019-$0.38-$0.29-$0.34 - -$0.18-31.03%MissN/A9N/AAug 1, 2019N/A
    Mar 31, 2019-$0.30-$0.29-$0.37 - -$0.18-3.45%MissN/A9N/AMay 7, 2019N/A
    Dec 31, 2018-$0.27-$0.26-$0.33 - -$0.22-3.85%MissN/A7N/AFeb 27, 2019N/A
    Sep 30, 2018-$0.36-$0.33-$0.36 - -$0.30-9.09%MissN/A7N/ANov 6, 2018N/A
    Jun 30, 2018-$0.34-$0.32-$0.34 - -$0.29-6.25%MissN/A7N/AAug 6, 2018N/A
    Mar 31, 2018-$0.31-$0.29-$0.33 - -$0.23-6.90%MissN/A6N/AMay 10, 2018N/A
    Dec 31, 2017-$0.32-$0.32-$0.34 - -$0.290.00%In lineN/A7N/AMar 12, 2018N/A
    Sep 30, 2017-$0.35-$0.29N/A-20.69%MissN/AN/AN/AOct 31, 2017N/A
    Jun 30, 2017-$0.37-$0.28N/A-32.14%MissN/AN/AN/AAug 1, 2017N/A
    Mar 31, 2017-$0.28-$0.27N/A-3.70%MissN/AN/AN/AMay 1, 2017N/A
    Dec 31, 2016-$0.25-$0.25N/A0.00%In lineN/AN/AN/AMar 7, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.12, after -$1.30 the year before. It was -$0.79 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.12N/A
    Dec 31, 2024-$1.30N/A
    Dec 31, 2023-$1.88N/A
    Dec 31, 2022-$2.48N/A
    Dec 31, 2021-$2.22N/A
    Dec 31, 2020-$1.89N/A
    Dec 31, 2019-$1.58N/A
    Dec 31, 2018-$1.28N/A
    Dec 31, 2017-$1.32N/A
    Dec 31, 2016-$0.79N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,69612
    2026Q2Jun 30, 20265,59211
    2026Q1Mar 31, 20265,03712
    2025Q4Dec 31, 20256,22919
    2025Q3Sep 30, 20255,47816
    2025Q2Jun 30, 20255,47215
    2025Q1Mar 31, 20257,20817
    2024Q4Dec 31, 20246,93717

    2026Q3 Earnings Call

    Opening remarks

    Jen Saunders Senior Director, Investor Relations and Corporate Communications Thank you, Daniel. Good morning, and welcome to the Iovance webcast to discuss our third quarter 2026 financial results, business achievements, and corporate updates. This morning, we issued a press release that is available on our corporate website at iovance.com. This conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue and revenue guidance, commercial activities, clinical trials and results, regulatory approvals, submissions, feedback and guidance, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, payer interactions, licenses and collaborations, cash position, and future updates. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected during today's call. We undertake no obligation to publicly update any forward-looking statements. I will now turn the call over to Dr. Fred Vogt, Interim CEO and President.

    Fred Vogt Interim CEO and President Thank you, Jen. Good morning, everyone. Our third quarter delivered outstanding record-setting results for Iovance, with our highest ever revenue and margin and strong financial performance across the board. Total revenue of about $122 million surged 80% over the prior year. U.S. AMTAGVI revenue increased 77% over the prior year and crossed $100 million in a single quarter for the first time. We also passed an important landmark this quarter, with more than 1,000 commercial AMTAGVI patients now infused in the U.S. since launch. Based on this strong performance, we remain on track to achieve our full-year revenue guidance of $410 million-$420 million. Our authorized treatment center, or ATC, network continues to expand rapidly, and we fully expect to reach 110 or more authorized treatment centers by year-end. Third quarter margin of about 60% also set a new all-time high for the second consecutive quarter, and we expect it to expand further over time. Our cash runway is now expected to fund operations well into 2029. This strong performance reflects the financial health of Iovance and the strong platform that we can build upon for upcoming launches. The third quarter and recent updates also reflect major progress across our TIL platform and pipeline programs. In metastatic non-small cell lung cancer, lifileucel continues to demonstrate a potentially best-in-class clinical profile. Earlier this year, the FDA granted fast-track designation based on the strength of our data and the high unmet need. Last week, we reported positive updated results from our registrational IOV-LUN-202 trial that included 69 patients with previously treated non-squamous metastatic non-small cell lung cancer. The objective response rate, or ORR, by RECIST 1.1 was 24.6%, consistent with our prior results in 39 patients.

    Frequently Asked Questions About IOVA

    When is Iovance Biotherapeutics's next earnings date?

    Iovance Biotherapeutics's next earnings report is expected for Feb 22, 2027.

    Did IOVA beat earnings estimates last quarter?

    Yes. Iovance Biotherapeutics reported EPS of -$0.05 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 44.44% surprise.

    What EPS do analysts expect from IOVA next quarter?

    The consensus EPS estimate for Iovance Biotherapeutics for the quarter ending Dec 31, 2026 is -$0.08 from 12 analysts, with estimates from -$0.12 to -$0.04.

    How often does IOVA beat earnings estimates?

    Iovance Biotherapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -0.14%.